228 related articles for article (PubMed ID: 29813187)
1. Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta.
Jeong Y; Daghlas SA; Xie Y; Hulbert MA; Pfeiffer FM; Dallas MR; Omosule CL; Pearsall RS; Dallas SL; Phillips CL
J Bone Miner Res; 2018 Oct; 33(10):1760-1772. PubMed ID: 29813187
[TBL] [Abstract][Full Text] [Related]
2. Soluble activin receptor type IIB decoy receptor differentially impacts murine osteogenesis imperfecta muscle function.
Jeong Y; Daghlas SA; Kahveci AS; Salamango D; Gentry BA; Brown M; Rector RS; Pearsall RS; Phillips CL
Muscle Nerve; 2018 Feb; 57(2):294-304. PubMed ID: 28555931
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial Inhibition of Myostatin and Activin A Improves Femoral Bone Properties in the G610C Mouse Model of Osteogenesis Imperfecta.
Omosule CL; Joseph D; Weiler B; Gremminger VL; Silvey S; Jeong Y; Rafique A; Krueger P; Kleiner S; Phillips CL
J Bone Miner Res; 2022 May; 37(5):938-953. PubMed ID: 35195284
[TBL] [Abstract][Full Text] [Related]
4. Impact of Genetic and Pharmacologic Inhibition of Myostatin in a Murine Model of Osteogenesis Imperfecta.
Omosule CL; Gremminger VL; Aguillard AM; Jeong Y; Harrelson EN; Miloscio L; Mastaitis J; Rafique A; Kleiner S; Pfeiffer FM; Zhang A; Schulz LC; Phillips CL
J Bone Miner Res; 2021 Apr; 36(4):739-756. PubMed ID: 33249643
[TBL] [Abstract][Full Text] [Related]
5. Whole-Body Metabolism and the Musculoskeletal Impacts of Targeting Activin A and Myostatin in Severe Osteogenesis Imperfecta.
Omosule CL; Joseph D; Weiler B; Gremminger VL; Silvey S; Lafaver BN; Jeong Y; Kleiner S; Phillips CL
JBMR Plus; 2023 Jul; 7(7):e10753. PubMed ID: 37457877
[TBL] [Abstract][Full Text] [Related]
6. Myostatin deficiency partially rescues the bone phenotype of osteogenesis imperfecta model mice.
Oestreich AK; Carleton SM; Yao X; Gentry BA; Raw CE; Brown M; Pfeiffer FM; Wang Y; Phillips CL
Osteoporos Int; 2016 Jan; 27(1):161-70. PubMed ID: 26179666
[TBL] [Abstract][Full Text] [Related]
7. Correlations Between Bone Mechanical Properties and Bone Composition Parameters in Mouse Models of Dominant and Recessive Osteogenesis Imperfecta and the Response to Anti-TGF-β Treatment.
Bi X; Grafe I; Ding H; Flores R; Munivez E; Jiang MM; Dawson B; Lee B; Ambrose CG
J Bone Miner Res; 2017 Feb; 32(2):347-359. PubMed ID: 27649409
[TBL] [Abstract][Full Text] [Related]
8. Decreasing maternal myostatin programs adult offspring bone strength in a mouse model of osteogenesis imperfecta.
Oestreich AK; Kamp WM; McCray MG; Carleton SM; Karasseva N; Lenz KL; Jeong Y; Daghlas SA; Yao X; Wang Y; Pfeiffer FM; Ellersieck MR; Schulz LC; Phillips CL
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13522-13527. PubMed ID: 27821779
[TBL] [Abstract][Full Text] [Related]
9. Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?
Boskey AL; Marino J; Spevak L; Pleshko N; Doty S; Carter EM; Raggio CL
Clin Orthop Relat Res; 2015 Aug; 473(8):2587-98. PubMed ID: 25903941
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Wnt signaling improves bone mass and strength, but not brittleness, in the Col1a1(+/mov13) mouse model of type I Osteogenesis Imperfecta.
Jacobsen CM; Schwartz MA; Roberts HJ; Lim KE; Spevak L; Boskey AL; Zurakowski D; Robling AG; Warman ML
Bone; 2016 Sep; 90():127-32. PubMed ID: 27297606
[TBL] [Abstract][Full Text] [Related]
11. Novel ActRIIB ligand trap increases muscle mass and improves bone geometry in a mouse model of severe osteogenesis imperfecta.
Tauer JT; Rauch F
Bone; 2019 Nov; 128():115036. PubMed ID: 31419601
[TBL] [Abstract][Full Text] [Related]
12. Compromised Exercise Capacity and Mitochondrial Dysfunction in the Osteogenesis Imperfecta Murine (oim) Mouse Model.
Gremminger VL; Jeong Y; Cunningham RP; Meers GM; Rector RS; Phillips CL
J Bone Miner Res; 2019 Sep; 34(9):1646-1659. PubMed ID: 30908713
[TBL] [Abstract][Full Text] [Related]
13. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
Sinder BP; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
Bone; 2015 Feb; 71():115-23. PubMed ID: 25445450
[TBL] [Abstract][Full Text] [Related]
14. Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta.
Roschger A; Roschger P; Keplingter P; Klaushofer K; Abdullah S; Kneissel M; Rauch F
Bone; 2014 Sep; 66():182-8. PubMed ID: 24953712
[TBL] [Abstract][Full Text] [Related]
15. Bone mineral properties in growing Col1a2(+/G610C) mice, an animal model of osteogenesis imperfecta.
Masci M; Wang M; Imbert L; Barnes AM; Spevak L; Lukashova L; Huang Y; Ma Y; Marini JC; Jacobsen CM; Warman ML; Boskey AL
Bone; 2016 Jun; 87():120-9. PubMed ID: 27083399
[TBL] [Abstract][Full Text] [Related]
16. Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.
Puolakkainen T; Ma H; Kainulainen H; Pasternack A; Rantalainen T; Ritvos O; Heikinheimo K; Hulmi JJ; Kiviranta R
BMC Musculoskelet Disord; 2017 Jan; 18(1):20. PubMed ID: 28103859
[TBL] [Abstract][Full Text] [Related]
17. Hindlimb Skeletal Muscle Function and Skeletal Quality and Strength in +/G610C Mice With and Without Weight-Bearing Exercise.
Jeong Y; Carleton SM; Gentry BA; Yao X; Ferreira JA; Salamango DJ; Weis M; Oestreich AK; Williams AM; McCray MG; Eyre DR; Brown M; Wang Y; Phillips CL
J Bone Miner Res; 2015 Oct; 30(10):1874-86. PubMed ID: 25829218
[TBL] [Abstract][Full Text] [Related]
18. Effect of rapamycin on bone mass and strength in the α2(I)-G610C mouse model of osteogenesis imperfecta.
Bateman JF; Sampurno L; Maurizi A; Lamandé SR; Sims NA; Cheng TL; Schindeler A; Little DG
J Cell Mol Med; 2019 Mar; 23(3):1735-1745. PubMed ID: 30597759
[TBL] [Abstract][Full Text] [Related]
19. Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.
Bargman R; Posham R; Boskey AL; DiCarlo E; Raggio C; Pleshko N
Osteoporos Int; 2012 Mar; 23(3):1141-50. PubMed ID: 21901481
[TBL] [Abstract][Full Text] [Related]
20. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.
Sinder BP; White LE; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
Osteoporos Int; 2014 Aug; 25(8):2097-107. PubMed ID: 24803333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
